A Study for Adults with a Diagnosis of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Why are we doing this research?
Cincinnati Children's is conducting a research study, sometimes known as a clinical trial or clinical study, to evaluate a treatment and confirm that the study drug, inhaled Molgramostim, improves the function of the lungs in adults with aPAP.
Who can participate?
Adults who have a diagnosis of aPAP may be eligible to be in this study.
Conditions
- Chest and Lungs - Respiratory Tract
What will happen in the study?
This study will last up to 108 weeks (about 2 years). It will require 17 visits to the clinic site.
Here are some of the things that will happen in this study:
You will:
- Be asked to perform screening tests and procedures to figure out if you qualify for the study. You will visit the clinic site 2 times (visit 1-2). You will not receive any treatment.
- Receive either the study drug or placebo every day for 48 weeks. You will visit the clinic site 9 times.
- If you complete the first 48 week, you may choose to receive study drug every day for another 48 weeks. You will visit the clinic site 4 times and have one phone call with the study team.
- A safety follow-up visit will occur 4 weeks later to ensure there has not been development of any late side effects.
What are the good things that can happen from this research?
There is a possibility that you will benefit from an improvement in your aPAP symptoms when you receive the study drug for at least 48 weeks.
What are the bad things that can happen from this research?
The most common risks or side effects are the following: cough, headache, chest pain, swelling of nasal passages or shortness of breath.
Will you/your child be paid to be in this research study?
If you complete this study, we may pay you up to $1,275.00.